Xella combines precision medicine, advanced at-home testing, and concierge clinical care to improve outcomes for women. Using menstrual fluid sampling, blood diagnostics, machine learning, and advanced sequencing, Xella translates complex biological data into clear, actionable insights tailored to female-specific conditions.

We deliver AI-powered risk assessment, early detection, and personalized care plans for fertility, endometriosis, PCOS, hormone and metabolic health, perimenopause/menopause, and gynecologic cancer risk. Xella pairs predictive models with clinician oversight to provide testing, continuous tracking, and telehealth coaching at an accessible price point.

Users choose at-home sampling (menstrual swab or blood draw) or in-person lab visits. Results appear in a secure digital portal with AI-powered interpretation, personalized action plans, and ongoing clinician support. Xella is launching Spring 2026 and currently offers early access/waitlist sign-up.